The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years ...
An active androgen receptor (AR) is required in CRPC. Post-translational modification plays an important role in AR activation and, ultimately, in the subset of genes targeted for transcription.
Androgen receptor (AR) signaling is the primary driver of prostate ... While castration negates AR signaling for a period of time, castration resistant prostate cancer (CRPC) emerges due to ...
Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...
Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.
News Medical on MSN8d
PROTAC technology offers hope for treating castration-resistant prostate cancerAnnouncing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.
The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide ... castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback